Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 139

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 139
---
 net earnings (loss), and allocates resources on a consolidated basis. The CODM uses net earnings (loss) to decide whether to reinvest profits into the Company's current products or into other research and development initiatives for the Company's product candidates. Net earnings (loss) is also used to monitor budget versus actual results.The measure of the reportable segment assets is reported on the balance sheet as total assets. 

30

The following table shows the segment revenue, significant segment expenses and net earnings (loss) (dollars in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024(unaudited)(unaudited)Total revenues$192,103 $175,689 $507,380 $487,658 Less: Significant segment expenses:Cost of goods sold18,965 17,583 51,555 51,808 Selling expenses58,386 38,082 145,398 116,190 Marketing expenses18,672 16,247 60,068 56,510 General and administrative expenses(a)33,114 15,424 86,833 69,473 Acquisition-related expenses(b)69,506 — 70,874 — Research and development expensesExternal development program expenses:ONAPGO352 71 1,613 1,164 SPN-8201,111 6,668 8,073 20,010 SPN-8174,872 2,815 11,889 5,835 Qelbree3,168 5,621 9,805 11,552 ZURZUVAE1,385 — 1,385 — Early-stage programs and other expenses5,173 4,343 11,865 12,516 Total external development program expenses16,061 19,518 44,630 51,077 Internal employee-related expenses13,305 9,518 33,778 29,072 Total research and development expenses29,366 29,036 78,408 80,149 Other segment items(c)9,211 20,820 48,689 54,991 Net earnings (loss)$(45,117)$38,497 $(34,445)$58,537 (a) Excludes Sage Acquisition related expenses which are presented in the separate line item, Acquisition-related expenses,